Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of Lunsekimig in Adults With Asthma
NCT06609239Phase 2Enrolling by invitation
- Sponsor
- Sanofi
- Start
- Sep 2024
- Primary completion
- Jan 2031
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 2, open-label, single-arm trial of lunsekimig in asthma, sponsored by Sanofi. Primary endpoint: Exposure-adjusted incidence rate of treatment-emergent adverse events at 148 weeks. Started Sep 2024; status: enrolling by invitation.
02
Drugs
lunsekimig
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06609239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06609239.